Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
ViewAttendees 6

A4. Treatment of antimicrobial resistant infections

Session: Late Breaker Abstracts

LB15 - SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics

Saturday, October 2, 2021
1:15 PM - 3:00 PM EDT
Participants should be aware of the following financial/non-financial relationships:
Timothy J. Straub, MS: Seres Therapeutics (Employee)
Liyang Diao, PhD: Seres Therapeutics (Employee)
Christopher Ford, PhD: Seres Therapeutics (Employee, Shareholder)
Matthew Sims, MD, PhD: Astra Zeneca (Independent Contractor)Diasorin Molecular (Independent Contractor)Epigenomics Inc (Independent Contractor)Finch (Independent Contractor)Genentech (Independent Contractor)Janssen Pharmaceuticals NV (Independent Contractor)Kinevant Sciences gmBH (Independent Contractor)Leonard-Meron Biosciences (Independent Contractor)Merck and Co (Independent Contractor)OpGen (Independent Contractor)Prenosis (Independent Contractor)Regeneron Pharmaceuticals Inc (Independent Contractor)Seres Therapeutics Inc (Independent Contractor)Shire (Independent Contractor)Summit Therapeutics (Independent Contractor)
Thomas J. Louie, MD: Artugen (Advisor or Review Panel member)Crestone (Consultant, Grant/Research Support)Da Volterra (Advisor or Review Panel member)Finch Therapeutics (Grant/Research Support, Advisor or Review Panel member)MGB Biopharma (Grant/Research Support, Advisor or Review Panel member)Rebiotix (Consultant, Grant/Research Support)Seres Therapeutics (Consultant, Grant/Research Support)Summit PLC (Grant/Research Support)Vedanta (Grant/Research Support, Advisor or Review Panel member)
Charles Berenson, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Colleen S. Kraft, MD, MSc: Rebiotix (Individual(s) Involved: Self): Advisor or Review Panel member
Stuart H. Cohen, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Alla Paskovaty, PharmD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mary-Jane Lombardo, PhD: Seres Therapeutics (Employee, Shareholder)
Barbara McGovern, MD: Seres Therapeutics (Employee, Shareholder)
Lisa von Moltke, MD: Seres Therapeutics (Employee, Shareholder)
Matt Henn, PhD: Seres Therapeutics (Employee, Shareholder)

    Presenting Author(s)

  • Timothy J. Straub, MS

    Scientist I
    Seres Therapeutics
    Cambridge, MA, United States

    Seres Therapeutics (Employee)

    • Co-Author(s)

  • LD

    Liyang Diao, PhD

    Seres Therapeutics
    Cambridge, Massachusetts, United States

    Seres Therapeutics (Employee)

  • CF

    Christopher Ford, PhD

    Director
    Seres Therapeutics, Inc
    Cambridge, MA, United States

    Seres Therapeutics (Employee, Shareholder)

  • MS

    Matthew Sims, MD, PhD

    Director of Infectious Diseases Research
    Beaumont Health
    Royal Oak, Michigan, United States

    Astra Zeneca (Independent Contractor)Diasorin Molecular (Independent Contractor)Epigenomics Inc (Independent Contractor)Finch (Independent Contractor)Genentech (Independent Contractor)Janssen Pharmaceuticals NV (Independent Contractor)Kinevant Sciences gmBH (Independent Contractor)Leonard-Meron Biosciences (Independent Contractor)Merck and Co (Independent Contractor)OpGen (Independent Contractor)Prenosis (Independent Contractor)Regeneron Pharmaceuticals Inc (Independent Contractor)Seres Therapeutics Inc (Independent Contractor)Shire (Independent Contractor)Summit Therapeutics (Independent Contractor)

  • Thomas J. Louie, MD

    Professor
    Cumming School of Medicine, University of Calgary, Calgary, Canada
    Calgary, Alberta, Canada

    Artugen (Advisor or Review Panel member)Crestone (Consultant, Grant/Research Support)Da Volterra (Advisor or Review Panel member)Finch Therapeutics (Grant/Research Support, Advisor or Review Panel member)MGB Biopharma (Grant/Research Support, Advisor or Review Panel member)Rebiotix (Consultant, Grant/Research Support)Seres Therapeutics (Consultant, Grant/Research Support)Summit PLC (Grant/Research Support)Vedanta (Grant/Research Support, Advisor or Review Panel member)

  • CB

    Charles Berenson, MD

    Associate Professor of Medicine
    State University of New York at Buffalo
    Buffalo, New York, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Colleen S. Kraft, MD, MSc

    Associate Professor
    Emory University
    Atlanta, GA, United States

    Rebiotix (Individual(s) Involved: Self): Advisor or Review Panel member

  • Stuart H. Cohen, MD

    Medical Director of Hospital Epidemiology; Division Chief, Infectious Diseases
    University of California, Davis
    Sacramento, California, United States

    Seres (Research Grant or Support)

  • AP

    Alla Paskovaty, PharmD

    Seres Therapeutics
    New York, New York, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • ML

    Mary-Jane Lombardo, PhD

    Seres Therapeutics, Inc
    Cambridge, Massachusetts, United States

    Seres Therapeutics (Employee, Shareholder)

  • BM

    Barbara McGovern, MD

    Vice President
    Seres Therapeutics, Inc.
    Cambridge, MA, United States

    Seres Therapeutics (Employee, Shareholder)

  • Lv

    Lisa von Moltke, MD

    Seres Therapeutics
    Cambridge, Massachusetts, United States

    Seres Therapeutics (Employee, Shareholder)

  • MH

    Matt Henn, PhD

    Chief Scientific Officer
    Seres Therapeutics, Inc.
    Cambridge, MA, United States

    Seres Therapeutics (Employee, Shareholder)